Always Smile With Daewoong

home Home > About Us > Press Release > News

뉴스
No	Subject	Data
274	The clinical findings of Botulinum Toxin manufactured by Daewoong have been published on international journal regarding the comparison with Botox	2019-04-12
273	Daewoong Pharmaceutical hosts a symposium for the 20th anniversary of release of Albis.	2019-04-03
272	The U.S. 3-phase clinical results of ‘Jeuveau’ is published on an SCI-level international journal	2019-03-25
271	Daewoong Pharmaceutical acquires the sales rights for Vivotif, an orally injected typhoid fever vaccine.	2019-03-19
270	Daewoong Pharmaceutical leads innovation of local business by focusing on technology transfer with Trapaco, the largest pharmaceuticals company in Vietnam.	2019-03-14
269	Daewoong Pharmaceutical ‘Nabota’ enters phase 3 clinical studies in China during the second half.	2019-03-13
268	Daewoong Pharmaceutical selected for government funding for DWN12088, a new medication for pulmonary fibrosis.	2019-03-08
267	Daewoong Pharmaceutical exceeds 1 trillion KRW in 2018 to reset the record.	2019-03-06
266	Daewoong Pharmaceutical has completed the lineup of hypertension medications with the approval of ‘Olomax.’	2019-02-28
265	Daewoong Pharmaceutical’s botulinum toxin becomes the first Korea-made Botulinum Toxin to obtain US FDA approval	2019-02-02

1 / 2 / 3 / 4 / 5 / 6 / 7 / 8 / 9 / 10 /